The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Limits of meta-analysis: methylphenidate in the treatment of adult attention-deficit hyperactivity disorder
Abstract
Abstract Guidelines for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults advocate methylphenidate as first-line treatment. The aim of this study was to review the effectiveness of methylphenidate treatment of adult ADHD and to examine the influence of methods on meta-analytic results. Electronic databases were searched to identify clinical trials comparing methylphenidate with placebo in the treatment of adult ADHD. Studies were summarised with meta-analytic methods. Subgroup analyses were conducted with respect to parallel group versus cross-over trials and self versus observer ratings. The relationship between dosage and effect size was explored by weighted regression analysis. The results were tested for publication bias, and several sensitivity analyses were performed. Findings and methods were compared with a previous meta-analysis. Eighteen studies met the inclusion criteria of which 16 were included in the meta-analysis. The overall effect size (d = 0.42) was significantly different from zero, but was only half the size expected on the basis of a previous meta-analysis. No significant differences could be observed in the subgroup analyses. The regression analysis showed no significant influence of mean daily dose on effect size. These results contradict findings of a previous meta-analysis and challenge guideline recommendations. Methodological issues in meta-analyses are discussed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“An increasing number of studies in adults demonstrate a similar clinical response to that seen in children [32,236-239].”
From European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD (2010) · cites this paper as [236]
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Wasserman, S. S., Hedges, L. V., & Olkin, I. (1988) · Journal of Educational Statistics · doi:10.2307/1164953 · Cited by 10,377
The file drawer problem and tolerance for null results.
Rosenthal, R. (1979) · Psychological Bulletin · doi:10.1037/0033-2909.86.3.638 · Cited by 9,068
Distribution Theory for Glass's Estimator of Effect Size and Related Estimators
Hedges, L. V. (1981) · Journal of Educational Statistics · doi:10.2307/1164588 · Cited by 5,695
Kessler, R. C., Adler, L., Barkley, R., Biederman, J., Conners, C. K., Demler, O., Faraone, S. V., Greenhill, L. L., Howes, M. J., Secnik, K., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.4.716 · Cited by 3,886
The Handbook of Research Synthesis.
Howel, D., Cooper, H., & Hedges, L. V. (1995) · Biometrics · doi:10.2307/2533295 · Cited by 3,657
Statistical Methods for Meta-Analysis
(1985) · Elsevier eBooks · doi:10.1016/c2009-0-03396-0 · Cited by 2,570
Morris, S. B., & DeShon, R. P. (2002) · Psychological Methods · doi:10.1037/1082-989x.7.1.105 · Cited by 2,502
Dichotomizing continuous predictors in multiple regression: a bad idea
Royston, P., Altman, D. G., & Sauerbrei, W. (2006) · Statistics in Medicine · doi:10.1002/sim.2331 · Cited by 2,312
Research works printed but not linked: 3
- Jadad AR, 1999, Evid Rep Technol Assess (Summ), 1
- The Nordic Cochrane Centre, 2003, Review Manager (RevMan) for Windows.
- Mattes JA, 1982, Psychopharmacol Bull, 18, 114
Cited by
Sorted by citations
Kooij, S. J., Bejerot, S., Blackwell, A., Caci, H., Casas-Brugué, M., Carpentier, P. J., Edvinsson, D., Fayyad, J., Foeken, K., Fitzgerald, M., et al. (2010) · BMC Psychiatry · doi:10.1186/1471-244x-10-67 · Cited by 928
“An increasing number of studies in adults demonstrate a similar clinical response to that seen in children [32,236-239].”
Updated European Consensus Statement on diagnosis and treatment of adult ADHD
Kooij, J. J. S., Bijlenga, D., Salerno, L., Jaeschke, R., Bitter, I., Balázs, J., Thome, J., Dom, G., Kasper, S., Nunes Filipe, C., et al. (2019) · European Psychiatry · doi:10.1016/j.eurpsy.2018.11.001 · Cited by 686
Medication for Attention Deficit–Hyperactivity Disorder and Criminality
Lichtenstein, P., Halldner, L., Zetterqvist, J., Sjölander, A., Serlachius, E., Fazel, S., Långström, N., & Larsson, H. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203241 · Cited by 611
Adult attention-deficit hyperactivity disorder: key conceptual issues
Asherson, P., Buitelaar, J., Faraone, S. V., & Rohde, L. A. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30032-3 · Cited by 347
Bolea-Alamañac, B., Nutt, D. J., Adamou, M., Asherson, P., Bazire, S., Coghill, D., Heal, D., Müller, U., Nash, J., Santosh, P., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881113519509 · Cited by 287
“Currently available evidence (level Ib) from randomised clinical trials points towards a low efficacy of methylphenidate in the treatment of ADHD in substance abuse populations (Koesters et al., 2009).”
BackgroundTreatment strategies for ADHD: an evidence-based guide to select optimal treatment
Caye, A., Swanson, J. M., Coghill, D., & Rohde, L. A. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0116-3 · Cited by 303
Stimulant ADHD medication and risk for substance abuse
Chang, Z., Lichtenstein, P., Halldner, L., D'Onofrio, B., Serlachius, E., Fazel, S., Långström, N., & Larsson, H. (2014) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.12164 · Cited by 225
“…to have advantageous short-term effects on ADHD symptoms (Adler et al., 2009; Banaschewski et al., 2006; Findling, 2008; Findling et al., 2008; Koesters et al., 2009; Kooij et al., 2010; Newcorn et al., 2008; Svanborg et al., 2009; Young et al., 2011), and similar to a study on drug-related…”
Advokat, C. (2010) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.03.006 · Cited by 219
Castells, X., Ramos-Quiroga, J. A., Rigau, D., Bosch, R., Nogueira, M., Vidal, X., & Casas, M. (2011) · CNS Drugs · doi:10.2165/11539440-000000000-00000 · Cited by 197
Philipsen, A., Jans, T., Graf, E., Matthies, S., Borel, P., Colla, M., Gentschow, L., Langner, D., Jacob, C., Groß-Lesch, S., et al. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.2146 · Cited by 175
Distinguishing comorbidity and successful management of adult ADHD
Kooij, J. J. S., Huss, M., Asherson, P., Akehurst, R., Beusterien, K., French, A., Sasané, R., & Hodgkins, P. (2012) · Journal of Attention Disorders · doi:10.1177/1087054711435361 · Cited by 172
“Current guidelines for the treatment of adult ADHD recommend MPH as first-line treatment (Koesters et al., 2009; National Institute for Health and Clinical Excellence [NICE], 2009).”
BackgroundEmotional dysregulation in adult ADHD: what is the empirical evidence?
Retz, W., Stieglitz, R., Corbisiero, S., Retz‐Junginger, P., & Rösler, M. (2012) · Expert Review of Neurotherapeutics · doi:10.1586/ern.12.109 · Cited by 188
Zetterqvist, J., Asherson, P., Halldner, L., Långström, N., & Larsson, H. (2013) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12004 · Cited by 155
Efficacy of Psychostimulant Drugs for Cocaine Dependence
Cervelló, X. C., Casas, M., Pérez‐Mañá, C., Roncero, C., Vidal, X., & Capellà, D. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007380.pub3 · Cited by 131
Rösler, M., Retz, W., Fischer, R., Ose, C., Alm, B., Deckert, J., Philipsen, A., Herpertz, S., & Ammer, R. (2010) · The World Journal of Biological Psychiatry · doi:10.3109/15622971003624197 · Cited by 131
Rucklidge, J., Frampton, C., Gorman, B., & Boggis, A. (2014) · British Journal of Psychiatry · doi:10.1192/bjp.bp.113.132126 · Cited by 117
“52 The improvements in global measures of functioning suggest that, whereas ADHD symptoms persist to some degree, micro-nutrient treatment appears to benefit a variety of areas of psychological functioning.”
Matthies, S. D., & Philipsen, A. (2014) · Borderline Personality Disorder and Emotion Dysregulation · doi:10.1186/2051-6673-1-3 · Cited by 110
“MPH treatment of adult ADHD should be part of a comprehensive treatment program that also addresses psychological and social aspects [92].”
BackgroundGinsberg, Y., & Lindefors, N. (2012) · British Journal of Psychiatry · doi:10.1192/bjp.bp.111.092940 · Cited by 83
“14,15 The placebo effect was negligible in this study, in sharp contrast to the significant placebo responses that have been reported in most previous studies.”
InfluentialZalsman, G., & Shilton, T. (2016) · International Journal of Psychiatry in Clinical Practice · doi:10.3109/13651501.2016.1149197 · Cited by 103
“A meta-analysis published by Koesters et al. (2009) reported an overall moderate effect of 0.42, with no dose-response effect.”
BackgroundInfluentialIs ADHD a valid diagnosis in adults? Yes
Asherson, P. J., Adamou, M., Bolea-Alamanac, B. M., Müller, U., Dunn-Morua, S., Pitts, M. E., Thome, J., & Young, S. (2010) · BMJ · doi:10.1136/bmj.c549 · Cited by 92
Is emotional dysregulation part of the psychopathology of ADHD in adults?
Corbisiero, S., Stieglitz, R.-D., Retz, W., & Rösler, M. (2013) · ADHD Attention Deficit and Hyperactivity Disorders · doi:10.1007/s12402-012-0097-z · Cited by 139
“This recommendation is corroborated by different meta-analyses demonstrating the significant effect of stimulants and atomoxetine (ATX) on the classical symptom triad (Castells et al. 2011; Faraone et al. 2004; Koesters et al. 2009; Meszaros et al. 2009).”
ResultCunill, R., Cervelló, X. C., Tobı́as, A., & Capellà, D. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4099-3 · Cited by 91
The relationship between ADHD and obesity: implications for therapy
Cortese, S., & Castellanos, F. X. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.904748 · Cited by 81
“, methylphenidate [14–17] or mixed amphetamine salts [18] and other amphetamines [19]) and some nonpsychostimulant treatments, such as atomoxetine [20–23], are significantly more efficacious than placebo, at least in the short term, when considering short-term change in ADHD core symptoms”
BackgroundPage, M. J., McKenzie, J. E., & Forbes, A. B. (2013) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2012.10.010 · Cited by 75
Clemow, D. B., & Bushe, C. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115602489 · Cited by 79
“7 (Castells et al., 2011; Koesters et al., 2009), which is similar to that observed for atomoxetine, where recent figures for ES of atomoxetine in adults include 0.”
ResultInfluentialPharmacological treatment of attention deficit hyperactivity disorder with co-morbid drug dependence
Cunill, R., Castells, X., Tobias, A., & Capellà, D. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114544777 · Cited by 78
“This effect size is smaller than that observed in other studies in which SUD was not an inclusion criterion (Castells et al., 2011, 2013; Cunill et al., 2013; Koesters et al., 2009).”
BackgroundResultTrends in Psychiatry and Psychotherapy
(2020) · Trends in Psychiatry and Psychotherapy · doi:10.47626/2237-6089 · Cited by 70
Kambeitz, J., Romanos, M., & Ettinger, U. (2014) · The Pharmacogenomics Journal · doi:10.1038/tpj.2013.9 · Cited by 64
Pharmacological Treatment of ADHD in Addicted Patients: What Does the Literature Tell Us?
Carpentier, P. J., & LEVIN, F. R. (2017) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000122 · Cited by 69
Retz, W., Rösler, M., Ose, C., Scherag, A., Alm, B., Philipsen, A., Fischer, R., Ammer, R., & The Study Group (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2010.540257 · Cited by 79
“More recently, an overall effect size of d ’ 0.42 was reported from a meta-analysis of 16 studies with methylphenidate in adult ADHD patients (Koesters et al. 2009).”
InfluentialSantosh, P. J., Sattar, S., & Canagaratnam, M. (2011) · CNS Drugs · doi:10.2165/11593070-000000000-00000 · Cited by 62
Koblan, K., Hopkins, S., Sarma, K., Jin, F., Goldman, R., Kollins, S., & Loebel, A. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.124 · Cited by 60
“…at week 4 overlapped with the range and 95% confidence intervals of those reported in meta-analyses of the DAT/NET inhibitor methylphenidate (Faraone et al, 2004; Koesters et al, 2009), but were smaller than the effect sizes reported for amphetamine-based medications (Faraone and Glatt, 2010).”
ResultImmediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults
Epstein, T., Patsopoulos, N. A., & Weiser, M. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005041.pub3 · Cited by 62
RetractedAmphetamines for attention deficit hyperactivity disorder (ADHD) in adults
Castells, X., Blanco-Silvente, L., & Cunill, R. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007813.pub3 · Cited by 209
Huss, M., Ginsberg, Y., Tvedten, T., Arngrim, T., Philipsen, A., Carter, K., Chen, C.-W., & Kumar, V. (2013) · Advances in Therapy · doi:10.1007/s12325-013-0085-5 · Cited by 61
“[33] from the meta-analysis of 18 studies comparing MPH with placebo in the treatment of adult ADHD.”
MethodImmediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults
Epstein, T., Patsopoulos, N. A., & Weiser, M. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005041.pub2 · Cited by 65
RetractedLong-term functional outcome in adult prison inmates with ADHD receiving OROS-methylphenidate
Ginsberg, Y., Hirvikoski, T., Grann, M., & Lindefors, N. (2012) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-012-0317-8 · Cited by 57
“Moreover, the few studies that have evaluated methylphenidate treatment in participants with ADHD and coexisting substance use disorder could not establish efficacy as compared with placebo in improving ADHD symptoms [31].”
BackgroundGeissler, J. M., & Lesch, K. (2011) · Expert Review of Neurotherapeutics · doi:10.1586/ern.11.136 · Cited by 57
Skirrow, C., McLoughlin, G., Banaschewski, T., Brandeis, D., Kuntsi, J., & Asherson, P. J. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.09.015 · Cited by 50
“Non-drug related effects of the treatment process on symptoms and impairments, are seen in all ADHD drug treatment trials of methylphenidate in adult ADHD (Koesters et al., 2009).”
BackgroundMorgensterns, E., Alfredsson, J., & Hirvikoski, T. (2016) · ADHD Attention Deficit and Hyperactivity Disorders · doi:10.1007/s12402-015-0182-1 · Cited by 48
“Clinical trials of pharmacotherapy have demonstrated positive short-term (Castells et al. 2011; Koesters et al. 2009; Torgersen et al. 2008) and possible positive long-term (Fredriksen et al. 2013) effects on the core ADHD symptoms.”
BackgroundAmphetamines for Attention Deficit Hyperactivity Disorder (ADHD) in adults
Castells, X., Ramos-Quiroga, J. A., Bosch, R., Nogueira, M., & Casas, M. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007813.pub2 · Cited by 80
Moukhtarian, T. R., Mintah, R. S., Moran, P., & Asherson, P. J. (2018) · Borderline Personality Disorder and Emotion Dysregulation · doi:10.1186/s40479-018-0086-8 · Cited by 54
Lau, B. W.-M., Yau, S., Lee, T. M. C., Ching, Y.-P., Tang, S.-W., & So, K. (2010) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2010.02081.x · Cited by 46
Cortese, S., Adamo, N., Jensen, C. M., Hayes, A. J., Bhatti, S., Carucci, S., Giovane, C. D., Atkinson, L. Z., Banaschewski, T., Simonoff, E. A., et al. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-013967 · Cited by 47
Asherson, P. J., Bushe, C., Saylor, K. E., Tanaka, Y., Deberdt, W. G., & Upadhyaya, H. P. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114542453 · Cited by 44
González, R. A., Kallis, C., & Coid, J. W. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075575 · Cited by 43
“Symptoms of ADHD can be treated effectively with medication in both children and adults [60,61,62,63].”
BackgroundPievsky, M. A., & McGrath, R. E. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.05.012 · Cited by 47
Optimal management of ADHD in older adults
Torgersen, T., Gjervan, B., Lensing, M. B., & Rasmussen, K. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s59271 · Cited by 42
Cornforth, C., Sonuga-Barke, E., & Coghill, D. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210791959827 · Cited by 41
“42) i n this area [122]; furthermore, this is also significantly lower than what has been generally re po ted in childhood.”
BackgroundStuhec, M., Lukić, P., & Locatelli, I. (2019) · Annals of Pharmacotherapy · doi:10.1177/1060028018795703 · Cited by 46
“In the literature, there are many different meta-analyses available in adults,(10-20) although many of them included only methylphenidate (MPH) immediate release form and similar forms of MPH excluding LDX and modafinil (MDF).(11,13,16,17,20) Also, there are only 4 meta-analyses available that included LDX and compare…”
BackgroundAddressing the lack of studies in attention-deficit/hyperactivity disorder in adults
Ramos‐Quiroga, J. A., Nasillo, V., Fernández‐Aranda, F., & Casas, M. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.908708 · Cited by 44
“42 The overall effect size was significantly different from zero, but was only half the size expected on the basis of a previous meta-analysis [87]”
ResultMoncrieff, J., & Timimi, S. B. (2013) · Anthropology and Medicine · doi:10.1080/13648470.2012.747591 · Cited by 39
“A recent meta-analysis found that there was no difference between stimulants and placebo in parallel group randomised trials in adults with ADHD, and that studies conducted by the Harvard group reported considerably larger effect sizes than other studies (Koesters et al. 2008).”
ResultNon-medical use of methylphenidate: a review
Freese, L., Signor, L., Machado, C. A., Ferigolo, M., & Barros, H. M. T. (2012) · Trends in Psychiatry and Psychotherapy · doi:10.1590/s2237-60892012000200010 · Cited by 38
Schubert, S. J., Hansen, S. E., Dyer, K. R., & Rapley, M. (2009) · Discourse & Society · doi:10.1177/0957926509104025 · Cited by 37
Pharmacological treatment of adult ADHD in Europe
Retz, W., Retz‐Junginger, P., Thome, J., & Rösler, M. (2011) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2011.603229 · Cited by 37
“More recently, an overall moderate effect size of 0.42 was reported from a meta-analysis of 16 studies with methylphenidate in adult ADHD patients (Koesters et al. 2009).”
InfluentialContini, V., Rovaris, D. L., Victor, M. M., Grevet, E. H., Rohde, L. A., & Bau, C. H. D. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.05.006 · Cited by 34
“Its efficacy and safety were also confirmed in meta-analytic studies (Castells et al., 2011; Faraone et al., 2004; Koesters et al., 2009) and MPH became the first choice in psychopharmacologic treatment in adults with ADHD (Nutt et al., 2007).”
BackgroundCobos, J. P. D. L., Siñol, N., Pérez, V., & Trujols, J. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12045 · Cited by 38
Bijlenga, D., Jasperse, M., Gehlhaar, S. K., & Sandra Kooij, J. J. (2015) · European Psychiatry · doi:10.1016/j.eurpsy.2014.06.003 · Cited by 34
“In the Netherlands, pharmacological treatment of adult ADHD is mostly with short- or long-acting methylphenidate or dexamphetamine [9], with considerable to very high effect sizes [5,8,4].”
BackgroundPerugi, G., Pallucchini, A., Rizzato, S., Pinzone, V., & Rossi, P. D. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1618270 · Cited by 35
Skoglund, C. B., Brandt, L., Almqvist, C., D'Onofrio, B. M., Konstenius, M., Franck, J., & Larsson, H. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000501 · Cited by 36
Muld, B. B., Jokinen, J., Bölte, S., & Hirvikoski, T. (2014) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2014.11.005 · Cited by 34
Castells, X., Cunill, R., & Capellà, D. (2013) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-012-1390-7 · Cited by 41
Retz, W., & Retz‐Junginger, P. (2014) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-014-0542-4 · Cited by 34
“30, was about half of those observed in other studies in which SUD was an exclusion criterion [16, 19].”
ADHD with comorbid substance use disorder: review of treatment
Magon, R., & Müller, U. (2012) · Advances in Psychiatric Treatment · doi:10.1192/apt.bp.111.009340 · Cited by 29
“Several meta-analyses of randomised clinical trials (Koesters 2009; Faraone 2010) and evidence-based guidelines suggest that stimulants should be the first option for treatment for adult ADHD (Nutt 2007; National Institute for Health and Clinical Excellence 2008).”
MethodInfluentialBushe, C., Day, K., Reed, V., Karlsdotter, K., Berggren, L., Pitcher, A., Televantou, F., & Haynes, V. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116636105 · Cited by 31
“The results of meta-analyses can reflect differing methodologies (Koesters et al., 2009) and the number of studies able to be included due to the time of analysis relative to the available information in the literature.”
BackgroundResultInfluentialAsherson, P. J., Stes, S., Markhed, M. N., Berggren, L., Svanborg, P., Kutzelnigg, A., & Deberdt, W. G. (2015) · European Psychiatry · doi:10.1016/j.eurpsy.2014.12.002 · Cited by 25
“This may be important because effect sizes for core ADHD symptoms and emotional control may differ according to the self-ratings versus observer ratings [3,21,31,47].”
BackgroundAttention Deficit Hyperactivity Disorder Medication Use Among Teens and Young Adults
Johansen, M. E., Matic, K., & McAlearney, A. S. (2015) · Journal of Adolescent Health · doi:10.1016/j.jadohealth.2015.04.009 · Cited by 24
Attention-deficit/hyperactivity disorder in adults: update on clinical presentation and care
Asherson, P. J., Manor, I., & Huß, M. (2014) · Neuropsychiatry · doi:10.2217/npy.14.16 · Cited by 27
Young, S., & Sedgwick, O. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1059756 · Cited by 32
“Few randomized controlled trials have assessed methylphenidate efficacy among those with ADHD and SUD, and despite some individual studies showing some positive effects, a meta-analysis of these trials in 2009 found effect sizes close to zero for both ADHD and SUD symptoms [56].”
BackgroundCritical analysis of the concept of adult attention-deficit hyperactivity disorder
Moncrieff, J., & Timimi, S. (2011) · The Psychiatrist · doi:10.1192/pb.bp.110.033423 · Cited by 18
Boesen, K., Saiz, L. C., Erviti, J., Storebø, O. J., Gluud, C. N., Gøtzsche, P. C., & Jørgensen, K. J. (2017) · BMJ Evidence-Based Medicine · doi:10.1136/ebmed-2017-110716 · Cited by 22
Muld, B. B., Jokinen, J., Bölte, S., & Hirvikoski, T. (2016) · ADHD Attention Deficit and Hyperactivity Disorders · doi:10.1007/s12402-016-0195-4 · Cited by 23
Haijen, E. C. H. M., Hurks, P. P. M., & Kuypers, K. P. C. (2022) · Neuroscience Applied · doi:10.1016/j.nsa.2022.101012 · Cited by 20
“Overall, 22 they have been proven to work effectively in adults with ADHD [14-16], inducing fast symptom 23 relief and thereby enhancing the person’s quality of life.”
BackgroundGinsberg, Y., Arngrim, T., Philipsen, A., Gandhi, P., Chen, C.-W., Kumar, V., & Huss, M. (2014) · CNS Drugs · doi:10.1007/s40263-014-0180-4 · Cited by 20
“Methylphenidate remains one of the most commonly prescribed medications for the treatment of ADHD in adults because of availability of efficacy and safety data [5–16].”
BackgroundMurphy, D., Glaser, K., Hayward, H., Eklund, H., Cadman, T., Findon, J., Woodhouse, E., Ashwood, K., Beecham, J., Bolton, P., et al. (2018) · Programme Grants for Applied Research · doi:10.3310/pgfar06020 · Cited by 18
“5.(324) This will include ratings of the DSM-IV ADHD items from the Conners’ Adult ADHD Rating Scales – Observer; and the associated symptoms of ‘emotional dysregulation’ from the Wender–Reimherr Adult ADHD Scale.”
MethodAsherson, P. J., Johansson, L. C., Holland, R., Fahy, T., Forester, A., Howitt, S., Lawrie, S. M., Strang, J., Young, S., Landau, S., et al. (2019) · Trials · doi:10.1186/s13063-019-3705-9 · Cited by 18
Torgersen, T., Gjervan, B., Rasmussen, K., Vaaler, A., & Nordahl, H. (2013) · ADHD Attention Deficit and Hyperactivity Disorders · doi:10.1007/s12402-012-0094-2 · Cited by 16
“The short-term efficacy of central stimulant (CS) drugs like methylphenidate (MPH) and amphetamine on symptoms of adult ADHD is generally reported to be good (Faraone and Glatt 2009; Koesters et al. 2009; Torgersen et al. 2008).”
BackgroundLinderkamp, F., & Lauth, G. W. (2011) · Verhaltenstherapie · doi:10.1159/000332429 · Cited by 18
Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults
Boesen, K., Paludan‐Müller, A. S., Gøtzsche, P. C., & Jørgensen, K. J. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012857.pub2 · Cited by 23
Bijlenga, D., Kulcu, S., van Gellecum, T., Eryigit, Z., & Kooij, J. J. S. (2017) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000787 · Cited by 16
Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults
Boesen, K., Danborg, P. B., Gøtzsche, P. C., & Jørgensen, K. J. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012857 · Cited by 11
Selaskowski, B., Staerk, C., Braun, N., Matthies, S., Graf, E., Colla, M., Jacob, C., Sobanski, E., Alm, B., Roesler, M., et al. (2022) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2022.03.049 · Cited by 11
Martins, A., Conte, M., Goettert, M. I., & Contini, V. (2023) · Inflammopharmacology · doi:10.1007/s10787-023-01339-1 · Cited by 8
“MPH stand as a first-line drug (Fredriksen et al. 2014; Surman et al. 2013) and numerous meta analyses have consistently demonstrated its efficacy and safety (Faraone et al. 2004; Koesters et al. 2009).”
OROS methylphenidate hydrochloride for adult patients with attention deficit/hyperactivity disorder
McBurnett, K., & Starr, H. L. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.546058 · Cited by 8
“However, a more recent and larger meta-analysis [34] reported an effect size of 0.”
BackgroundAre the effects of methylphenidate uncertain?
Cortese, S. (2018) · Irish Journal of Psychological Medicine · doi:10.1017/ipm.2018.16 · Cited by 9
“Despite previous systematic reviews and metaanalyses pointing to high effect sizes, when considering the efficacy of MPH for the reduction of ADHD symptoms in the short term (e.g. Schachter et al. 2001; Van der Oord et al. 2008; Koesters et al. 2009; Castells et al. 2011), a recent systematic review and metaanalysis b…”
BackgroundShould we Keep on? Looking into Pharmacogenomics of ADHD in Adulthood from a Different Perspectives
Rovaris, D. L., Mota, N. R., da Silva, B. S., Girardi, P., Victor, M. M., Grevet, E. H., Bau, C. H. D., & Contini, V. (2014) · Pharmacogenomics · doi:10.2217/pgs.14.95 · Cited by 7
TDA/H, trouble de l’enfance ou de l’âge adulte ?
Ilario, C., Alt, A., Bader, M., & Sentissi, O. (2019) · L Encéphale · doi:10.1016/j.encep.2019.05.004 · Cited by 7
Management of ADHD in Prisoners—Evidence Gaps and Reasons for Caution
Tully, J. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.771525 · Cited by 10
“However, evidence for prescribing of stimulant and othermedication in ADHDhas been fraught with inconsistencies (98, 99) and beset by controversy (5, 100–102).”
BackgroundCoetzee, C., Schellekens, A., Truter, I., & Meyer, A. (2022) · European Addiction Research · doi:10.1159/000526386 · Cited by 6
Attention-Deficit Hyperactivity Disorder and Autism Spectrum Disorder
Cortese, S. (2016) · Springer eBooks · doi:10.1007/978-3-319-29695-1_6 · Cited by 5
Sleep Disturbances in Attention-Deficit/Hyperactivity Disorder
Cortese, S., & Lecendreux, M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-24288-2.00141-0 · Cited by 5
Medikamentöse Therapie der Aufmerksamkeitsdefizit‑/Hyperaktivitätsstörung im Erwachsenenalter
Retz, W., Retz‐Junginger, P., Davydenko, S., & Rösler, M. (2020) · Der Nervenarzt · doi:10.1007/s00115-020-00891-3 · Cited by 5
ADHD in Adults: A Clinical Concern
Asherson, P. J. (2012) · Humana Press eBooks · doi:10.1007/978-1-62703-248-3_1 · Cited by 7
Psychostimulanzien und verwandte Substanzen bei psychisch Kranken
Kölch, M. G., Plener, P. L., & Fegert, J. M. (2011) · Springer eBooks · doi:10.1007/978-3-642-19844-1_60 · Cited by 4
Self-citationAttention-deficit hyperactivity disorder and exposure to nature in college students
Thal, L. (2014) · MOspace Institutional Repository (University of Missouri) · doi:10.32469/10355/44338 · Cited by 4
“…& 4 Biederman, 2004; Koesters, Becker, Kilian, Fegert, & Weinmann, 2009), and although they both concluded that the medication had a significant effect on symptoms of adult ADHD compared to placebo, Koesters et al. (2009) found an effect size less than half of that found by Faraone et al. (2004).”
ResultPsychopharmacological Treatment of Attention-Deficit Hyperactivity Disorder in Adults
Trott, G. (2009) · Key issues in mental health (Online)/Key issues in mental health (Print) · doi:10.1159/000258456 · Cited by 2
Torgersen, T., Krokstad, S., & Vaaler, A. E. (2014) · ADHD Attention Deficit and Hyperactivity Disorders · doi:10.1007/s12402-014-0135-0 · Cited by 4
“In the present study, we found that few patients with adult ADHD improved in occupational status during long-term CS treatment despite adequate doses (Koesters et al. 2009; Faraone and Glatt 2010; Torgersen et al. 2008; Wender et al. 2011; Reimherr et al. 2007) and duration of treatment.”
BackgroundInfluentialOROS-methylphenidate to reduce ADHD symptoms in male prisoners aged 16–25 years: a RCT
Asherson, P. J., Johansson, L., Holland, R., Bedding, M., Forrester, A., Giannulli, L., Ginsberg, Y., Howitt, S., Kretzschmar, I., Lawrie, S. M., et al. (2022) · Efficacy and Mechanism Evaluation · doi:10.3310/thei8200 · Cited by 4
Pharmakotherapie der ADHS im Erwachsenenalter
Ludolph, A. G., Connemann, B. J., & Brummer, D. (2010) · Nervenheilkunde · doi:10.1055/s-0038-1628716 · Cited by 3
Pharmacotherapy of ADHD in Adults
Rösler, M., Retz, W., & Turner, D. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_254 · Cited by 3
Metadata
- Authors
- Koesters, M., Becker, T., Kilian, R., Fegert, J., & Weinmann, S.
- Affiliations
- Universität Ulm (DE)
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2008-06-18
- Volume
- 23
- Issue
- 7
- Pages
- 733-744
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W2171147935
- Cited by
- 142
- References
- 58
- Citations by year
- 2026: 1 · 2024: 1 · 2023: 1 · 2022: 8 · 2021: 2 · 2020: 3 · 2019: 6 · 2018: 8 · 2017: 9 · 2016: 11 · 2015: 11 · 2014: 18 · 2013: 12 · 2012: 19
- FWCI
- 7.48
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- AstraZeneca
- BERLIN-CHEMIE
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Social Sciences › Decision Sciences › Statistics, Probability and Uncertainty › Meta-analysis and systematic reviews
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- adult ADHD, methylphenidate, treatment effectiveness, publication bias, dose-response relationship, clinical trial design, treatment guidelines
- MeSH terms
- Adult, Attention Deficit Disorder with Hyperactivity, Humans, Methylphenidate, Sensitivity and Specificity, Meta-Analysis as Topic, Randomized Controlled Trials as Topic, Treatment Outcome, Practice Guidelines as Topic, Publication Bias
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
